Open AccessHyperbilirubinemia following lenalidomide administration
Author(s) -
Azmy Veronica,
Neparidze Natalia
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1471
Subject(s) - medicine , lenalidomide , discontinuation , asymptomatic , liver disease , drug , disease , intensive care medicine , pediatrics , pharmacology , multiple myeloma
Key Clinical Message Asymptomatic hyperbilirubinemia in a patient with no underlying liver disease or renal impairment while on lenalidomide therapy may be attributable to the unmasking of previously undiagnosed Gilbert's syndrome, as previously shown in the literature. The hyperbilirubinemia should resolve after discontinuation of the drug.